Stay updated on Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.
Latest updates to the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page
- Check3 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3.SummaryDifference0.0%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.4%
- Check31 days agoNo Change Detected
- Check38 days agoChange DetectedNew clinical studies have been added across various locations including multiple sites in the United States, Argentina, Brazil, and Europe, while several previous entries have been removed, including studies in Jerusalem and Swansea.SummaryDifference22%
- Check43 days agoChange DetectedDifference0.5%
- Check45 days agoChange DetectedThe study has expanded to include 151 locations and has been updated from revision v2.9.7 to v2.10.0.SummaryDifference0.6%
- Check49 days agoChange DetectedDifference0.5%
Stay in the know with updates to Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.